Solidion Technology Inc (STI) Stock News

A Delaware federal court ruled on September 30, 2026, that Liquidia Corporation's lead product Yutrepia inhalation powder infringed two claims of United Therapeutics' patent for treating pulmonary hypertension. The ruling triggered a sharp 57.2% stock price decline from $70.69 to $30.26 per share. Liquidia's CEO stated the company plans to pursue appellate options. A law firm is now investigating potential securities law violations on behalf of stockholders.

Block & Leviton is investigating Millrose Properties for potential securities fraud, alleging the company misled investors about its business dealings with Lennar. A report claimed Millrose purchased approximately $200 million of finished Lennar homes at above retail prices and is renting them at a loss. The stock declined following the report and a subsequent analyst downgrade.

Block & Leviton is investigating Lennar Corporation for potentially misleading investors about home delivery numbers in fiscal Q3 2026. The investigation focuses on whether Lennar artificially inflated delivery figures through purchases by its spinoff company Millrose Properties in the final week of the quarter. Lennar's stock fell on October 5, 2026, following an analyst downgrade of Millrose.

Law firm Kirby McInerney LLP is investigating potential securities law violations by uniQure N.V. following the release of 48-month data for AMT-130 that showed significantly reduced treatment efficacy (44% disease slowing) compared to previously reported 36-month results (75% slowing). The company had submitted an FDA application based on the stronger 36-month data. uniQure's stock price declined 37.3% on the news, falling from $39.11 to $24.51 per share.

Law firm Johnson Fistel is investigating NeoVolta, Inc. following the company's September 23, 2026 financial disclosures that revealed a $13,460 fourth-quarter revenue figure, a $3.9 million provision for credit losses, and a $1.54 million nonoperating credit loss on a note. The stock fell approximately 24% on September 24. The investigation focuses on whether the company adequately disclosed the condition of its residential business, customer receivables, and the timing of when a anticipated transaction with a borrower became unlikely.

Law firm Kirby McInerney LLP is investigating Medline Inc. for potential federal securities law violations following an FDA warning letter in June 2026 detailing significant manufacturing practice violations. The company's stock declined 7.2% on the FDA announcement and another 12.8% in August after Medline disclosed earnings losses from remediation efforts including product recalls.

Law firm Bernstein Liebhard announced an investigation into potential breaches of fiduciary duty by directors and officers of Embecta Corp. The firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. Current shareholders who purchased shares before November 25, 2025 are encouraged to contact the firm regarding their legal rights.

Block & Leviton is investigating Fluence Energy for potential securities law violations related to misleading statements about manufacturing capabilities. The company cut its full-year revenue outlook twice in August and September 2026, citing production delays at its Houston facility. Fluence reduced fiscal 2026 revenue guidance to $2.4 billion and adjusted EBITDA to a $200 million loss, causing sharp declines in share price. Investors who purchased Fluence Energy common stock and experienced losses may be eligible to recover damages.

Law firm Kirby McInerney LLP is investigating potential securities law violations by Cooper Companies following the company's September 9, 2026 earnings announcement. CooperCompanies reported Q3 revenue of $1.07 billion, missing analyst expectations of $1.10 billion, with its CooperVision segment showing flat year-over-year growth. The company attributed underperformance to proactive U.S. channel inventory reductions. The stock declined 14.7% on the news, falling from $63.48 to $54.17 per share.

Instinct Bio announced progress on its Indonesia expansion, securing a 213 m² premises in South Jakarta for its first GENRÊVER CLINIC site targeting opening by end of December 2026, with subscription pricing at $400-$3,000 monthly. The company is developing cosmetic product lines with manufacturing partners INVITRX (US-based) and PT PARVA CANDELA (Indonesia-based), with production targeted for 2026.

Law firm Bragar Eagel & Squire is investigating Sionna Therapeutics after the company announced its SION-719 Phase 2a trial failed to achieve its primary endpoint for sweat chloride reduction. The stock price fell over 91% following the announcement. The firm is encouraging affected shareholders to contact them regarding potential securities law violations.

Testie Health, a consumer health company founded by Thea Rose, has launched nationwide with a direct-to-lab STI testing model that allows customers to purchase testing panels online and visit nearby laboratories for sample collection without scheduling a doctor's appointment. The service aims to destigmatize routine STI testing and make it a normal part of preventive healthcare, with results delivered within 48 hours and licensed provider support available for positive results.

Block & Leviton is investigating CVRx, Inc., Papa John's International, and HubSpot for potential securities fraud. CVRx cut its revenue guidance citing sales force challenges and reimbursement issues, while HubSpot experienced a 25% share price decline. Investors who have suffered losses are encouraged to contact the firm.

Law firm Bragar Eagel & Squire is investigating Myriad Genetics for potential securities violations following the company's disappointing Q2 2026 earnings report. Myriad reported revenue of $190.7 million, down 11% year-over-year and significantly below consensus estimates. The company slashed full-year 2026 revenue guidance from $860-$880 million to $770-$790 million and suspended EBITDA guidance, citing reimbursement pressure, collection issues, and weak prenatal performance. This represents a dramatic $90 million midpoint cut just three months after reiterating prior guidance in May 2026.

Law firm Bragar Eagel & Squire is investigating HCA Healthcare for potential federal securities law violations following the company's July 14, 2026 announcement of sharply lowered full-year profit guidance due to unfavorable payer mix changes impacting revenue by approximately $400 million. HCA's stock fell 6.95% ($27.14 per share) to $363.60 on the news. The firm is seeking stockholders who suffered losses to participate in the action.

Law firm Bragar Eagel & Squire is investigating Alnylam Pharmaceuticals for potential federal securities law violations following the company's July 30, 2026 announcement of a $200 million reduction in TTR product sales guidance. The guidance cut, attributed to normalization of growth after initial market launch, triggered a 28.35% intraday stock price decline. The firm is seeking stockholders who suffered losses to participate in potential litigation.

Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Gartner, Inc. The law firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. The investigation targets shareholders who purchased shares before February 24, 2025.

Bernstein Liebhard LLP announced an investigation into potential breaches of fiduciary duty by directors and officers of Calix, Inc. The law firm is seeking to determine whether company leadership fulfilled its obligations to shareholders. The investigation focuses on shareholders who purchased shares before January 28, 2026.

Bernstein Liebhard LLP, an investor rights law firm, has announced investigations into potential breaches of fiduciary duty by directors and officers at AeroVironment, Capricor Therapeutics, and Calix. The firm is seeking to determine whether company leadership fulfilled obligations to shareholders and whether legal remedies may be available. Current shareholders are encouraged to contact the firm for consultation.

Bernstein Liebhard LLP has launched investigations into potential breaches of fiduciary duty by directors and officers at CarMax, Inc., Capricor Therapeutics, Inc., and Calix, Inc. The firm is seeking to determine whether company leadership acted in shareholders' best interests and is encouraging affected shareholders to contact them for legal consultation.

Block & Leviton is investigating T1 Energy for potential securities law violations following the company's disclosure of a 20% increase in capital expenditures for its G2_Austin solar-cell facility and a delay in production timeline. The stock fell approximately 22% after the announcement. The investigation focuses on whether the company previously reassured investors about budget and timeline while cost pressures were building.

Law firm Bragar Eagel & Squire is investigating IBM for potential securities law violations following the company's July 14, 2026 announcement of Q2 2026 results that fell short of analyst expectations. CEO Arvind Krishna attributed the shortfall to weakness in software and infrastructure businesses as customers shifted budgets to hardware like memory chips. IBM's stock price dropped 24.6% following the news, prompting the firm to encourage affected investors to contact them.

Law firm Bragar Eagel & Squire is investigating Astrotech Corporation following a Fugazi Research short report alleging repeated business model shifts, limited commercial success, and governance concerns including concentrated leadership roles under CEO Thomas Boone Pickels III and related-party conflict issues. The investigation follows a significant stock price decline.

Law firm Bragar Eagel & Squire is investigating VenHub Global for potential federal securities law violations. VenHub reported minimal revenue of $864,450 in FY 2025 against a net loss of $62.4 million, with significant balance sheet concerns including a stockholders' deficit of $10.3 million and working capital deficit of $9.2 million. The company disclosed substantial doubt about its ability to continue operations without additional capital.

Law firm Bragar Eagel & Squire is investigating Copart, Inc. following the announcement that CEO Jeff Liaw will step down effective July 31, 2026. The news triggered an 8.02% stock price decline ($2.45 per share) on June 29, 2026. The firm is seeking stockholders who suffered losses to discuss potential securities law violations and unlawful business practices.

Law firm Bragar Eagel & Squire is investigating Pentair plc for potential securities law violations following the company's July 15, 2026 announcement of significantly lowered 2026 outlook, $170 million inventory destocking impact on Pool segment sales, and immediate CFO departure. Pentair's stock fell 15% ($11.35) to $64.33 per share on the news.

Girard Sharp LLP is investigating potential securities claims on behalf of former Blue Owl Technology Finance Corp. II investors who received shares in the merger with Blue Owl Technology (NYSE: OTF) on March 24, 2025. Since the NYSE listing on June 13, 2025, Blue Owl Technology's share price has declined over 30%, with the investigation focusing on potential undisclosed issues with the fund's investment portfolios.

Law firm Robbins Geller Rudman & Dowd LLP has launched an investigation into The Ensign Group, Inc. following a Muddy Waters Research report alleging deception at approximately 20% of facilities with potential multi-billion dollar liability. The report triggered a decline in Ensign's stock price. The firm is seeking investors and witnesses with information about potential federal securities law violations.

Bernstein Liebhard LLP, an investor rights law firm, is investigating whether certain directors and officers of Gartner, Inc. breached fiduciary duties owed to the company. The firm is seeking shareholders who owned Gartner stock prior to February 24, 2025, to discuss their legal rights and options.

Bernstein Liebhard LLP, an investor rights law firm, is investigating whether certain directors and officers of CarMax, Inc. breached fiduciary duties owed to the company. The firm is seeking shareholders who purchased shares prior to June 20, 2025, to discuss their legal rights and options.